首页>
外国专利>
Peptides are derived from protein HMGB1 for active immuno-therapy of lethal systematic inflammation, such as septicemia, endotoxic shock, hemorrhagic shock and other correlated syndromes
Peptides are derived from protein HMGB1 for active immuno-therapy of lethal systematic inflammation, such as septicemia, endotoxic shock, hemorrhagic shock and other correlated syndromes
Peptides are derived from the protein HMGB1 for active immuno-therapy of lethal systematic inflammation, such as septicemia, endotoxic shock, hemorrhagic shock and other correlated syndromes. The affections to be combated are derived from a significant and anomalous presence of the protein HMGB1 in the biological fluid, particularly in the vascular region. The peptides contain immunogens in sufficient quantity to initiate the release of specific antibodies capable of neutralizing the biological activity of the endogenous HMGB1 molecule present in the vascular system, in particular it has the capacity of promoting and sustaining the cytokinetic TNF-alpha which is pro-inflammatory.
展开▼
